Fathi Halaweish

Dr. Fathi Halaweish


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
Fardous F. El-SendunyFardous F. El-Senduny
Fardous F. El-Senduny
FBFarid A. Badria
Farid A. Badria
AEAhmed M. El-Waseef
Ahmed M. El-Waseef
SCSubhash C. Chauhan
Subhash C. Chauhan
FHFathi Halaweish
Fathi Halaweish

1 June 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YEYaseen Elshaier
Yaseen Elshaier
MSMohamed A. Shaaban
Mohamed A. Shaaban
MHMohammed K. Abd El Hamid
Mohammed K. Abd El Hamid
MAMostafa H. Abdelrahman
Mostafa H. Abdelrahman
MAMahrous AbouSalim
Mahrous AbouSalim
FHFathi Halaweish
Fathi Halaweish

14 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MSMohammed Sikander
Mohammed Sikander
SMShabnam Malik
Shabnam Malik
Neeraj ChauhanNeeraj Chauhan
Neeraj Chauhan
PKParvez Khan
Parvez Khan
SKSonam Kumari
Sonam Kumari
Subhash ChauhanSubhash Chauhan
Subhash Chauhan
Prostate cancer (PrCa) metastasis is the major cause of mortality and morbidity among men. Metastatic PrCa cells are typically adopted for aberrant glucose metabolism. Thus, chemophores that reprogram altered glucose metabolic machinery in cancer cells can be useful agent for the repression of PrCa metastasis. Herein, we report that cucurbitacin D (Cuc D) effectively inhibits glucose uptake and lactate production in metastatic PrCa cells via modulating glucose metabolism. This metabolic shift by Cuc D was correlated with decreased expression of GLUT1 by its direct binding as suggested by its proficient molecular docking (binding energy −8.5 kcal/mol). Cuc D treatment also altered the expression of key oncogenic proteins and miR-132 that are known to be involved in glucose metabolism. Cuc D (0.1 to 1 µM) treatment inhibited tumorigenic and metastatic potential of human PrCa cells via inducing apoptosis and cell cycle arrest in G2/M phase. Cuc D treatment also showed inhibition of tumor growth in PrCa xenograft mouse model with concomitant decrease in the expression of GLUT1, PCNA and restoration of miR-132. These results suggest that Cuc D is a novel modulator of glucose metabolism and could be a promising therapeutic modality for the attenuation of PrCa metastasis.

31 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
MSMohammed Sikander
Mohammed Sikander
Shabnam MalikShabnam Malik
Shabnam Malik
SKSheema Shabir Khan
Sheema Shabir Khan
SKSonam Kumari
Sonam Kumari
Neeraj ChauhanNeeraj Chauhan
Neeraj Chauhan
Subhash ChauhanSubhash Chauhan
Subhash Chauhan
Pancreatic cancer (PanCa) is one of the leading causes of death from cancer in the United States. The current standard treatment for pancreatic cancer is gemcitabine, but its success is poor due to the emergence of drug resistance. Natural products have been widely investigated as potential candidates in cancer therapies, and cucurbitacin D (Cuc D) has shown excellent anticancer properties in various models. However, there is no report on the therapeutic effect of Cuc D in PanCa. In the present study, we investigated the effects of the Cuc D on PanCa cells in vitro and in vivo. Cuc D inhibited the viability of PanCa cells in a dose and time dependent manner, as evident by MTS assays. Furthermore, Cuc D treatment suppressed the colony formation, arrest cell cycle, and decreased the invasion and migration of PanCa cells. Notably, our findings suggest that mucin 13 (MUC13) is down-regulated upon Cuc D treatment, as demonstrated by Western blot and qPCR analyses. Furthermore, we report that the treatment with Cuc D restores miR-145 expression in PanCa cells/tissues. Cuc D treatment suppresses the proliferation of gemcitabine resistant PanCa cells and inhibits RRM1/2 expression. Treatment with Cuc D effectively inhibited the growth of xenograft tumors. Taken together, Cuc D could be utilized as a novel therapeutic agents for the treatment/sensitization of PanCa.

1 January 2015 in Cancer Letters
Verified
Journal Article
Closed access
DMDiane M. Maher
Diane M. Maher
SKSheema Khan
Sheema Khan
JNJordan L. Nordquist
Jordan L. Nordquist
MEMara C. Ebeling
Mara C. Ebeling
NBNichole A. Bauer
Nichole A. Bauer
Subhash ChauhanSubhash Chauhan
Subhash Chauhan

1 February 2017 in Steroids
Verified
Journal Article
Closed access
AAAbdulrhman Alsayari
Abdulrhman Alsayari
LKLucas Kopel
Lucas Kopel
MAMahmoud Ahmed
Mahmoud Ahmed
APAdam Pay
Adam Pay
TCTaylor Carlson
Taylor Carlson
FHFathi Halaweish
Fathi Halaweish